Scientific deep-dive

What Is the Best GLP-1 for Weight Loss? Ranked by FDA Evidence (2026)

There is no single best GLP-1. Zepbound leads on weight loss (20.9% in SURMOUNT-1) versus Wegovy 14.9%, Foundayo 11.2%, and Saxenda 8.0%. Wegovy has the only positive cardiovascular outcomes trial (SELECT, HR 0.80), and Foundayo is the oral, no-needle option.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
13 min read·7 citations

There is no single “best” GLP-1 for weight loss — there are four FDA-approved GLP-1 anti-obesity medications in 2026 (Saxenda, Wegovy, Zepbound, Foundayo) plus one investigational pipeline contender (retatrutide), and each ranks differently depending on whether you weight magnitude, cardiovascular protection, oral route, cost, or injection frequency. The honest answer is: Zepbound wins on raw weight-loss magnitude (−20.9% in SURMOUNT-1[2]), Wegovy wins on cardiovascular outcomes evidence (the only positive MACE trial in the class[6]), Foundayo wins on oral route and lowest needle-aversion friction, and Saxenda generic (Teva liraglutide, August 2025) wins on price among injectables. Here is the evidence-graded ranking with verbatim phase 3 endpoints.

About this article

Every drug ranked below is FDA-approved with a published label on DailyMed (NIH-hosted). Phase 3 efficacy is sourced from the canonical pivotal trial publications cited in PubMed and the verbatim FDA prescribing information. Pricing was as of May 2026 from manufacturer self-pay portals (NovoCare, LillyDirect) and Amazon Pharmacy. DailyMed SetIDs: Wegovy ee06186f-2aa3-4990-a760-757579d8f77b; Zepbound 487cd7e7-434c-4925-99fa-aa80b1cc776b; Foundayo 8ac446c5-feba-474f-a103-23facb9b5c62; Saxenda 3946d389-0926-4f77-a708-0acb8153b143. For the broader landscape, see our GLP-1 complete guide and the full GLP-1 medication reference.

TL;DR — the criterion-dependent answer

  • Best by raw %TBWL (magnitude): Zepbound (tirzepatide 15 mg weekly). −20.9% at 72 weeks in SURMOUNT-1[2]. Confirmed superior to semaglutide in the head-to-head SURMOUNT-5 trial[3].
  • Best by cardiovascular outcomes evidence: Wegovy (semaglutide 2.4 mg weekly). The SELECT trial[6] is the only chronic-weight-management GLP-1 trial with a positive MACE outcome (HR 0.80, 20% relative reduction in CV death / MI / stroke) in adults with established CVD and overweight or obesity without diabetes.
  • Best for oral route / needle aversion: Foundayo (orforglipron 17.2 mg oral daily). FDA-approved April 1, 2026. The first small-molecule (non-peptide) oral GLP-1 for chronic weight management. −11.2% at 72 weeks in ATTAIN-1[4].
  • Best by cash-pay cost (2026): Foundayo at $149/month at LillyDirect or Amazon Pharmacy ties as cheapest brand-name path; the new Teva generic liraglutide 3 mg (FDA-approved August 28, 2025) is the first generic GLP-1 receptor agonist for weight management and a price-disruption event for the Saxenda channel.
  • Pipeline / future winner: Retatrutide (Eli Lilly LY3437943, GIP / GLP-1 / glucagon triple agonist) hit −24.2% body weight at 48 weeks in its phase 2 trial[7]. Investigational — not FDA-approved. Phase 3 TRIUMPH program reads out throughout 2026.

Cross-trial efficacy comparisons across STEP-1, SURMOUNT-1, ATTAIN-1, and SCALE are indirect — the trials enrolled different populations and ran different durations. The only direct head-to-head trial in the chronic weight-management class is SURMOUNT-5 (tirzepatide vs semaglutide); we cover it in detail below. For the deeper molecule-level tirzepatide vs semaglutide pharmacology, see our tirzepatide vs semaglutide head-to-head guide.

Ranking by weight-loss magnitude (cross-trial indirect comparison)

Magnitude comparison

Mean percent total body-weight loss at the pivotal trial endpoint for every FDA-approved GLP-1 anti-obesity medication, plus the retatrutide pipeline phase 2 readout. Cross-trial comparison: trials enrolled different populations and ran different durations. Direct head-to-head data is limited to SURMOUNT-5 (tirzepatide vs semaglutide).[1][2][3][4][5][7]

  • Saxenda — liraglutide 3 mg daily (SCALE, 56 wk)8.0 % TBWL
    smallest effect; once-daily injection
  • Foundayo — orforglipron 17.2 mg oral daily (ATTAIN-1, 72 wk)11.2 % TBWL
    first small-molecule oral GLP-1 for weight
  • Wegovy — semaglutide 2.4 mg weekly (STEP-1, 68 wk)14.9 % TBWL
    best cardiovascular outcomes evidence
  • Zepbound — tirzepatide 15 mg weekly (SURMOUNT-1, 72 wk)20.9 % TBWL
    highest FDA-approved magnitude
  • Retatrutide — 12 mg phase 2 (48 wk) — investigational24.2 % TBWL
    NOT FDA-approved
Mean percent total body-weight loss at the pivotal trial endpoint for every FDA-approved GLP-1 anti-obesity medication, plus the retatrutide pipeline phase 2 readout. Cross-trial comparison: trials enrolled different populations and ran different durations. Direct head-to-head data is limited to SURMOUNT-5 (tirzepatide vs semaglutide).

The ranking by magnitude is unambiguous in direction: Zepbound > Wegovy > Foundayo > Saxenda among FDA-approved options, with retatrutide above all of them on phase 2 data but not yet a real-world prescription. The bars are indirect because the trials differed; the direct head-to-head data point that nails the Zepbound > Wegovy direction is SURMOUNT-5, covered next.

For readers weighing liraglutide: as of November 2026, Novo Nordisk plans to stop supplying Saxenda, with last shipments to wholesalers in late January 2027. FDA-approved generic liraglutide 3 mg exists, and a prescriber can help pick a replacement.[8]

The head-to-head trial: SURMOUNT-5 (tirzepatide vs semaglutide)

SURMOUNT-5[3] is the first FDA-quality randomized direct comparison of tirzepatide (the molecule in Zepbound and Mounjaro) vs semaglutide (the molecule in Wegovy and Ozempic) in adults with obesity without type 2 diabetes — the exact population covered by the chronic weight-management indications on both labels. The trial randomized adults with BMI ≥30 (or ≥27 with one weight-related comorbidity other than diabetes) to tirzepatide maintenance (up to 15 mg weekly) vs semaglutide maintenance (up to 2.4 mg weekly) over 72 weeks.

The result: tirzepatide produced greater mean weight loss than semaglutide across the primary and key secondary endpoints. This is the empirical anchor for the “Zepbound > Wegovy on magnitude” statement — it is no longer cross-trial inference, it is a randomized direct comparison published in NEJM 2025. For verbatim trial design + endpoint table + how it changes the prescribing conversation, see our tirzepatide vs semaglutide head-to-head guide.

Ranking by cardiovascular outcomes evidence

The cardiovascular outcomes ranking inverts the magnitude ranking. Wegovy wins decisively:

  • SELECT trial[6] (Lincoff NEJM 2023, n=17,604) randomized adults with established CVD (prior MI, stroke, or symptomatic PAD) and overweight or obesity (BMI ≥27) without diabetes to semaglutide 2.4 mg weekly vs placebo. The primary endpoint was 3-point MACE (cardiovascular death, non-fatal MI, non-fatal stroke). Result: HR 0.80 (95% CI 0.72–0.90), p<0.001 — a 20% relative reduction in MACE. Mean follow-up ~40 months.
  • Zepbound: No published cardiovascular outcomes trial in the chronic weight-management population to date. SURPASS-CVOT is the corresponding tirzepatide CVOT but enrolled patients with type 2 diabetes (not the weight-management indication); it showed noninferiority to dulaglutide for MACE (HR 0.92).
  • Foundayo: No CVOT. ATTAIN-1[4] measured weight as primary; cardiovascular outcomes are not yet established at trial-quality level.
  • Saxenda: The LEADER trial measured cardiovascular outcomes with liraglutide 1.8 mg in type 2 diabetes (not the 3.0 mg weight-management dose). It is not a Saxenda CVOT.

For patients with established CVD or high cardiovascular risk, Wegovy is the only FDA-approved weight-management GLP-1 with a positive randomized CV outcome. Some payers (Medicare Part D notably) added Wegovy CV-risk-reduction coverage in 2024 specifically based on SELECT, which expands access independent of the BMI-only weight indication. For the policy implication, see our GLP-1 Medicare/Medicaid/commercial coverage guide.

Ranking by route: oral vs injectable

If needle aversion is the dominant constraint, the ranking collapses to two pills: Foundayo is the first small-molecule (non-peptide) oral GLP-1 for chronic weight management, and the second after the Wegovy pill (oral semaglutide 25 mg, approved December 2025). Orforglipron is a non-peptide small-molecule, which means it does not require the strict fasting protocol Rybelsus (oral semaglutide, T2D-indicated) demands. Per the Foundayo §2 dosing label, the tablet can be taken with or without food. If you're paying cash, the independent clinicians on Sesame's marketplace publish prices for both pills, and our oral GLP-1 provider rankings compare the other telehealth services that prescribe them.

Cross-trial: Foundayo's −11.2% in ATTAIN-1[4] sits between Saxenda's −8.0% in SCALE[5] and Wegovy's −14.9% in STEP-1[1]. That is meaningfully less weight loss than Wegovy or Zepbound, but it is one of two oral paths in the FDA-approved GLP-1 class for weight management, alongside the Wegovy pill. For the deeper Foundayo vs Wegovy vs Zepbound comparison see our Foundayo vs Wegovy vs Zepbound comparison and the broader oral GLP-1 pills comparison.

Ranking by cash-pay cost (2026 manufacturer self-pay paths)

Our comparison of weight loss shots tracks what the injectables cost each month through telehealth. For uninsured patients or insured patients facing high deductibles or non-coverage, the cash-pay rank order by starting price (as of November 2026) is:

DrugManufacturer cash-pay pathMonthly
FoundayoLillyDirect Self Pay (0.8 mg and 2.5 mg; $199/mo at 5.5 mg, $299/mo at 9 mg and above)$149/mo
Wegovy (oral pill 1.5 mg)NovoCare Pharmacy ($199/mo at 4 mg)$149/mo
Zepbound (vials, 2.5–15 mg)LillyDirect Self Pay ($449/mo on 7.5 mg and above when refilled within 45 days)$299–$449/mo
Wegovy (standard pen 0.25–2.4 mg)NovoCare Pharmacy self-pay ($199/mo for a new patient's first two fills at 0.25/0.5 mg)$349/mo
Wegovy HD (7.2 mg pen)NovoCare Pharmacy self-pay$399/mo
Generic liraglutide 3 mgTeva (FDA-approved Aug 27, 2025) — first generic GLP-1 RA for weight managementrolling out; price disruption expected

For the channel-by-channel deeper cost breakdown including Costco Member Value Pricing, Sam's Club Plus Pharmacy, and GoodRx coupon mechanics, see our Zepbound vs Wegovy cost comparison and the live GLP-1 pricing index.

Compare vetted compounded semaglutide providers

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

No insurance needed · HSA/FSA eligible · vetted by our editors

8.3

Collective

The lowest flat medication price if you can absorb an annual membership fee

Starting price: $59/mo (+ required membership)

Get started →Read review Collective →
8.3

CoreAge Rx

Lowest-price compounded semaglutide and tirzepatide with one flat price at every dose

Starting price: $79/mo (“starting at” price)

Get started →Read review CoreAge Rx →
7.8

Embody

Low flat-rate compounded GLP-1 pricing at every dose

Starting price: $79/mo (sale price)

Get started →Read review Embody →
8.2

Gala

Compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping

Starting price: $129/mo (starting dose)

Get started →Read review Gala →
8.3

Found

Medication-included compounded GLP-1 from $169/mo on a 12-month prepaid plan, plus brand insurance help

Starting price: $169/mo (12-month plan rate)

Get started →Read review Found →

Ranking by side-effect profile

Across all four FDA-approved GLP-1 weight-management drugs, the §6 Adverse Reactions tables are dominated by GI events — nausea, diarrhea, vomiting, constipation. The magnitudes vary modestly but are not the meaningful differentiator across the class:

  • Wegovy §6.1: nausea ~44%, diarrhea ~30%, vomiting ~24%, constipation ~24% (label pool of three 68-week trials).
  • Zepbound §6.1: nausea ~28%, diarrhea ~23%, vomiting ~13%, constipation ~11% at 15 mg (label pool of SURMOUNT-1 and -2; constipation is highest, ~17%, at 5 mg).
  • Foundayo §6.1: GI events are most common; oral pharmacokinetics produce a different absorption curve than injectable depots, which in some patients translates to milder peak GI symptoms.
  • Saxenda §6.1: nausea ~39%, diarrhea ~21%, constipation ~19%, vomiting ~16% (SCALE).

All four labels carry the class boxed warning for thyroid C-cell tumors. For Wegovy, Zepbound, and Saxenda it rests on rodent carcinogenicity studies (human relevance not determined); for Foundayo it is class-based, because orforglipron is not active in rats or mice and produced no rodent tumors. All four are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). All four carry warnings for acute pancreatitis, gallbladder disease, acute kidney injury (from volume depletion secondary to GI loss), and hypoglycemia (especially when combined with sulfonylureas or insulin). Wegovy, Zepbound, and Foundayo also warn about diabetic retinopathy complications in type 2 diabetes. For the side-effect compare directly between Zepbound and Wegovy see our Zepbound vs Wegovy side effects.

“Best” depends on YOUR goal — a decision framework

Pick the row that matches your dominant constraint and the right answer falls out:

Your goalBest FDA-approved GLP-1Why
Maximum mean weight lossZepbound−20.9% in SURMOUNT-1; SURMOUNT-5 head-to-head confirms superiority over semaglutide
Cardiovascular risk reductionWegovyOnly positive MACE trial in class (SELECT, HR 0.80)
Oral instead of injectionFoundayoFirst small-molecule oral GLP-1 for chronic weight management; no fasting protocol
Lowest cash-pay costFoundayo or generic liraglutide$149/mo at LillyDirect/Amazon (Foundayo); Teva generic liraglutide is first FDA-approved generic GLP-1 RA for weight
Heart-failure with preserved EF (HFpEF) + obesityWegovySTEP-HFpEF results support functional and weight outcomes; see our STEP-HFpEF article
Adolescent (age 12–17)Wegovy or SaxendaWegovy approved for adolescents per STEP-TEENS; Saxenda approved for adolescents 12+
Obstructive sleep apnea (OSA)ZepboundOnly FDA-approved GLP-1 with the OSA indication (SURMOUNT-OSA, Dec 2024)
Chronic kidney disease + obesityWegovy (off-label CKD) / Ozempic (T2D CKD)FLOW trial supports semaglutide renal protection in T2D + CKD; chronic weight management indication is Wegovy

Common bad takes (and why they are wrong)

  • “Highest %TBWL is always best.” Wrong. Weight loss magnitude is one criterion. For a patient with established CVD, the +6% incremental weight loss from Zepbound vs Wegovy does not outweigh the only MACE-positive trial in the class (SELECT[6]). For a patient with severe needle aversion, even the highest-magnitude injectable is worse than the oral alternative they will actually take.
  • “Ozempic and Wegovy are different drugs.” Wrong. Same molecule (semaglutide), different brand names tied to different FDA indications. Ozempic is labeled for type 2 diabetes; Wegovy is labeled for chronic weight management. The maximum dose differs (Ozempic 2 mg vs Wegovy 7.2 mg, with 2.4 mg as Wegovy’s standard dose). For the deeper disambiguation see our Wegovy / Ozempic / Zepbound / Mounjaro brand-name cheat sheet.
  • “Mounjaro is better than Zepbound for weight loss.” Wrong. Same molecule (tirzepatide), different FDA indications. Mounjaro is the type-2-diabetes-indicated brand; Zepbound is the chronic-weight-management-indicated brand. For the disambiguation see our Mounjaro vs Zepbound tirzepatide disambiguation.
  • “Compounded semaglutide is just as good as Wegovy.” Not equivalent. Compounded semaglutide is not FDA-approved. The FDA enforcement-discretion grace period that allowed broad compounding during the semaglutide drug-shortage classification ended February 2025. There is no FDA-trial efficacy or safety data for compounded versions specifically. For the regulatory framing see our compounded tirzepatide vs compounded semaglutide guide.
  • “Retatrutide is the new best GLP-1.” Premature. Retatrutide is investigational and not FDA-approved. The −24.2% phase 2 headline number[7] is genuinely the highest published weight loss in the GLP-1-class pipeline, but phase 2 data routinely does not replicate at phase 3 scale, and safety + long-term tolerability profiles mature only at FDA submission. The phase 3 TRIUMPH program reads out throughout 2026. Until then, Zepbound is the highest-magnitude FDA-approved option. For the detailed pipeline walk-through see our retatrutide triple agonist evidence.

Bottom line

  • By raw weight-loss magnitude: Zepbound (tirzepatide 15 mg). −20.9% in SURMOUNT-1; confirmed superior to semaglutide in the SURMOUNT-5 head-to-head.
  • By cardiovascular outcomes evidence: Wegovy (semaglutide 2.4 mg). Only positive MACE trial in the chronic-weight-management class (SELECT, HR 0.80).
  • By oral route / needle aversion: Foundayo (orforglipron 17.2 mg oral). The first small-molecule (non-peptide) oral GLP-1 receptor agonist for chronic weight management.
  • By cost (cash-pay 2026): Foundayo $149/mo or generic liraglutide 3 mg (Teva, FDA-approved August 27, 2025 — the first generic GLP-1 RA for weight management).
  • Pipeline future winner: Retatrutide phase 2 −24.2%, but investigational, not FDA-approved, and TRIUMPH phase 3 data is the gating event throughout 2026.

There is no single “best GLP-1 for weight loss” in the abstract. The question always carries an unstated criterion: best for what. Once the criterion is named, the FDA-evidence-graded answer is unambiguous.

Key terms, explained

New to GLP-1s? Tap any term for a quick, plain-English definition.

Frequently Asked Questions

There is no single 'best' GLP-1 — the answer depends on your criterion. By raw % total body-weight loss at trial endpoint, Zepbound (tirzepatide 15 mg weekly) is the highest-magnitude FDA-approved option: -20.9% at 72 weeks in SURMOUNT-1 (Jastreboff NEJM 2022, PMID 35658024). The SURMOUNT-5 head-to-head trial (Aronne NEJM 2025, PMID 40353578) confirmed tirzepatide produces greater weight loss than semaglutide directly. By cardiovascular outcomes evidence, Wegovy (semaglutide 2.4 mg) wins decisively — the SELECT trial (Lincoff NEJM 2023, PMID 37952131) is the only positive MACE outcome trial in the chronic-weight-management GLP-1 class (HR 0.80). By oral route, Foundayo (orforglipron, FDA-approved April 2026) is the first small-molecule oral GLP-1 for weight management, and the second pill after the Wegovy pill (December 2025). By cash-pay cost in 2026, Foundayo at $149/month ties as cheapest brand-name path.
In direct head-to-head data, yes for mean weight loss. SURMOUNT-5 (Aronne NEJM 2025, PMID 40353578) was the first FDA-quality randomized trial to compare tirzepatide (the molecule in Zepbound and Mounjaro) vs semaglutide (the molecule in Wegovy and Ozempic) for chronic weight management in adults with obesity without diabetes; tirzepatide produced greater mean weight loss. Cross-trial: Zepbound SURMOUNT-1 -20.9% at 15 mg vs Wegovy STEP-1 -14.9% at 2.4 mg. That said, Wegovy has cardiovascular outcomes evidence that Zepbound does not — the SELECT trial (Lincoff NEJM 2023, PMID 37952131) showed a 20% relative MACE reduction with semaglutide in adults with established CVD and obesity without diabetes. SURPASS-CVOT (tirzepatide CVOT) enrolled T2D patients, not the weight-management population, and showed noninferiority to dulaglutide for MACE.
Among FDA-approved GLP-1s, Zepbound (tirzepatide 15 mg weekly) is the highest-magnitude option — SURMOUNT-1 reported -20.9% mean body-weight change at 72 weeks (PMID 35658024). The investigational pipeline contender retatrutide (Eli Lilly LY3437943, GIP/GLP-1/glucagon triple agonist) hit -24.2% at 48 weeks in its phase 2 trial (Jastreboff NEJM 2023, PMID 37366315) — that is the highest %TBWL published anywhere in the GLP-1 class — but retatrutide is investigational and NOT FDA-approved. The phase 3 TRIUMPH program reads out throughout 2026.
Wegovy (semaglutide 2.4 mg weekly) is the only FDA-approved chronic-weight-management GLP-1 with a positive cardiovascular outcomes trial. The SELECT trial (Lincoff NEJM 2023, PMID 37952131, n=17,604) randomized adults with established CVD (prior MI, stroke, or symptomatic PAD) and overweight or obesity without diabetes to semaglutide 2.4 mg vs placebo; the primary endpoint of 3-point MACE (CV death, non-fatal MI, non-fatal stroke) showed HR 0.80 (95% CI 0.72-0.90, p<0.001), a 20% relative reduction. Zepbound has no comparable published CVOT in the weight-management population; SURPASS-CVOT (tirzepatide in T2D, not weight management) showed noninferiority to dulaglutide for MACE (HR 0.92). Foundayo and Saxenda do not have weight-management CVOT data.
Foundayo (orforglipron 17.2 mg oral daily, Eli Lilly, FDA-approved April 1 2026) is the first small-molecule (non-peptide) oral GLP-1 receptor agonist for chronic weight management; the Wegovy pill (oral semaglutide 25 mg, approved December 22, 2025) is the other oral option. The pivotal ATTAIN-1 phase 3 trial (Wharton NEJM 2025, PMID 40960239) reported -11.2% mean body-weight change at 72 weeks on the highest trial dose (36 mg). Foundayo is a non-peptide small-molecule GLP-1 receptor agonist (not a peptide like semaglutide), so it does not require the fasting protocol Rybelsus does — it can be taken with or without food per the §2 dosing label. Starting at $149/month at LillyDirect Self Pay Pharmacy as of November 2026 (0.8 mg and 2.5 mg doses), rising to $199/month for 5.5 mg and $299/month for 9 mg and above. Rybelsus (oral semaglutide) is FDA-approved for type 2 diabetes, NOT for chronic weight management.
For brand-name cash-pay, Foundayo (orforglipron) and Wegovy oral pill (1.5 mg; $199 at 4 mg) tie at $149/month at LillyDirect/Amazon Pharmacy and NovoCare Pharmacy respectively. Wegovy standard injection pen is $349/month at NovoCare. Zepbound vials are $299-$449/month at LillyDirect. The Teva generic liraglutide 3 mg (FDA-approved August 28 2025) is the first FDA-approved generic GLP-1 receptor agonist for chronic weight management in the US — a price-disruption event for the Saxenda channel. Compounded semaglutide is NOT FDA-approved; the FDA enforcement-discretion grace period that allowed broad compounding ended February 2025.
Retatrutide (Eli Lilly LY3437943) is investigational and NOT FDA-approved. Its phase 2 trial (Jastreboff NEJM 2023, PMID 37366315) reported -24.2% mean body-weight change at 48 weeks on the highest dose — the highest %TBWL published anywhere in the GLP-1 class to date. Retatrutide is a triple GIP/GLP-1/glucagon receptor agonist. The phase 3 TRIUMPH program is ongoing with readouts throughout 2026. Phase 2 data routinely does not fully replicate at phase 3 scale, and FDA submission timing depends on the phase 3 data. Until FDA approval, retatrutide is not a real prescription — Zepbound is the highest-magnitude FDA-approved option.
The comparison is confounded by labeling. Ozempic (semaglutide) is FDA-approved for type 2 diabetes, NOT for chronic weight management — its weight-management twin (same molecule, higher 2.4 mg standard dose and up to 7.2 mg) is Wegovy. Zepbound (tirzepatide) IS FDA-approved for chronic weight management. On the underlying molecules, the SURMOUNT-5 head-to-head trial (Aronne NEJM 2025, PMID 40353578) showed tirzepatide produced greater mean weight loss than semaglutide in adults with obesity without diabetes. Cross-trial magnitude: Zepbound SURMOUNT-1 -20.9% vs semaglutide STEP-1 -14.9%. So for raw weight-loss magnitude, tirzepatide (Zepbound/Mounjaro) beats semaglutide (Wegovy/Ozempic). The caveat: semaglutide has the only positive cardiovascular outcomes trial in the class (SELECT, PMID 37952131). If your real question is Zepbound vs the weight-management brand of semaglutide, that is Zepbound vs Wegovy — Ozempic is the diabetes brand.
It depends heavily on your starting weight, which drug and dose, adherence, and diet/activity — and it is not medical advice. As a rough guide, 20 lb is about 10% of body weight for a 200 lb adult. GLP-1 weight loss is gradual during the multi-week dose-escalation phase and tends to accelerate near the maintenance dose. In STEP-1, semaglutide (Wegovy) reached roughly 10% mean loss around the 5–7 month mark on the way to -14.9% at 68 weeks; in SURMOUNT-1, tirzepatide (Zepbound) generally reached that threshold faster on the way to -20.9% at 72 weeks. Heavier starting individuals hit a fixed 20 lb sooner because it is a smaller percentage of their body weight. These are trial averages — individual results vary widely, and losing weight faster than the trial trajectory is not a goal in itself. Discuss expectations with your prescriber.

References

  1. 1.Wilding JPH, Batterham RL, Calanna S, et al. (STEP 1 Study Group) Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. PMID: 33567185.
  2. 2.Jastreboff AM, Aronne LJ, Ahmad NN, et al. (SURMOUNT-1 Investigators) Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. PMID: 35658024.
  3. 3.Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025. PMID: 40353578.
  4. 4.Wharton S, Aronne LJ, Stefanski A, et al. (ATTAIN-1 Investigators) Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Adults with Obesity (ATTAIN-1). N Engl J Med. 2025. PMID: 40960239.
  5. 5.Pi-Sunyer X, Astrup A, Fujioka K, et al. (SCALE Obesity and Prediabetes NN8022-1839 Study Group) A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes). N Engl J Med. 2015. PMID: 26132939.
  6. 6.Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (SELECT Trial Investigators) Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023. PMID: 37952131.
  7. 7.Jastreboff AM, Kaplan LM, Frías JP, et al. (Retatrutide Phase 2 Obesity Trial Investigators) Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. PMID: 37366315.
  8. 8.Novo Nordisk Inc. Saxenda Discontinuation Notice: advance notice that Saxenda will be discontinued, with last shipments to wholesalers in late January 2027. NovoCare. 2026. https://www.novocare.com/obesity/products/saxenda.html

Compounded Tirzepatide vs Compounded Semaglutide: Differences, Efficacy, Storage & Stability

Tirzepatide acts on GIP and GLP-1 and produced −20.9% weight loss in SURMOUNT-1, versus −14.9% for semaglutide in STEP-1. How the compounded versions compare on fridge life, regulatory status since Feb 2025 and additives like B12.

12 min read

Peptide Shots for Weight Loss: What the Evidence Actually Shows

'Peptide shots for weight loss' bundles the GLP-1 drugs — which ARE peptides with 15-21% trial results — with research chemicals that have none. We sort injectable peptides by human evidence: GLP-1s and cagrilintide have it; BPC-157, AOD-9604 and CJC-1295 do not.

13 min read

Weight Loss Injections Guide 2026 — Every FDA-Approved Option, Effectiveness, Cost, Safety

Three FDA-approved injections treat chronic weight: Zepbound (−20.9% at 72 weeks), Wegovy (−14.9% at 68 weeks) and Saxenda (−8.0% at 56 weeks). Plus off-label Ozempic and Mounjaro, the pipeline and 2026 cash prices.

18 min read

Foundayo vs Wegovy: Head-to-Head Evidence Comparison

Foundayo (orforglipron) is an oral small-molecule GLP-1 tablet; Wegovy (semaglutide) is a weekly injection or daily tablet. ATTAIN-1 ~11.1% weight loss vs STEP-1 ~14.9% and OASIS 4 (tablet) ~13.6%. Trial data, side effects, CV evidence, dosing rules, and a decision framework.

14 min read

Is Wegovy the Same as Semaglutide? Brand vs Generic Disambiguation

Wegovy IS semaglutide — the brand name for semaglutide 2.4 mg injection, FDA-approved for chronic weight management. Ozempic and Rybelsus are also semaglutide brands at different doses. No FDA-approved generic Wegovy exists as of 2026. Quick explainer with FDA-label sourcing.

7 min read

Ozempic & Wegovy Results Timeline: What to Expect Week by Week & Month by Month (2026)

What to expect on Ozempic and Wegovy (semaglutide) week by week and month by month. The STEP-1 trial averaged ~14.9% body-weight loss at 68 weeks — see the realistic timeline, why your results differ, and what's normal vs a reason to call your provider.

11 min read

Where to get tirzepatide (Mounjaro / Zepbound) safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

8.1

Oak

Compounded semaglutide and tirzepatide at a low starting price, with a full price list before you sign up

Read full review →

From $250/mo (starting dose)

Get started →
7.8

SnagRx

Compounded semaglutide and tirzepatide at a flat lifetime price

Read full review →

From $149/mo

Get started →
7.1

AgelessRx

Longevity-focused GLP-1 care with microdosing and brand-name options

Read full review →

From $209/mo (2-month plan rate)

Get started →